Morning Symposium 8

Early use of subcutaneous methotrexate MTX can shift the treatment trajectory by improving disease control, reducing side effects, and delaying other therapies. It is particularly valuable for patients with oral intolerance or inadequate response to oral MTX.

Therefore subcutaneous MTX plays an increasingly important role in the treatment of rheumatoid arthritis (RA) because it offers clinical advantages compared to oral use:

• Greater Clinical Efficacy
  Studies show that patients switched from oral to subcutaneous MTX often achieve lower disease activity scores and higher remission rates.
• Reduced Gastrointestinal Side Effects
  GI intolerance (nausea, vomiting) is a common reason for discontinuing oral MTX. Subcutaneous MTX significantly lowers these side effects, improving treatment adherence and drug survival.
• Potential First-Line Option
  Some European guidelines now recommend subcutaneous MTX as a first-line treatment for RA due to its efficacy and safety profile.
• Improved Bioavailability
  Oral MTX absorption is limited, especially at higher doses. Subcutaneous administration provides more consistent and higher bioavailability, which can lead to better disease control.”